首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Sex Hormone Receptors in Benign and Malignant Salivary Gland Tumors: Prognostic and Predictive Role
【2h】

Sex Hormone Receptors in Benign and Malignant Salivary Gland Tumors: Prognostic and Predictive Role

机译:良性和恶性唾液腺肿瘤中的性激素受体:预后和预测作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The role of sex hormone receptors in human cancer development and progression has been well documented in numerous studies, as has the success of sex hormone antagonists in the biological therapy of many human tumors. In salivary gland tumors (SGTs), little and conflicting information about the role of the estrogen receptor alpha (ERα), progesterone receptor (PgR) and androgen receptor (AR) has been described and in most cases the use of sex hormone antagonists is not contemplated in clinical practice. In this study, we analyzed a panel of sex hormone receptors that have not been widely investigated in SGTs—ERα, PgR, AR, but also ERβ and GPR30—to define their expression pattern and their prognostic and predictive value in a case series of 69 benign and malignant SGTs. We showed the aberrant expression of AR in mucoepidermoid and oncocytic carcinoma, a strong relation between cytoplasmic ERβ expression and tumor grade, and a strong correlation between nuclear GPR30 expression and disease-free survival (DFS) of SGT patients.
机译:性激素受体在人类癌症发生和发展中的作用已在许多研究中得到了充分证明,性激素拮抗剂在许多人类肿瘤的生物治疗中也取得了成功。在唾液腺肿瘤(SGTs)中,关于雌激素受体α(ERα),孕激素受体(PgR)和雄激素受体(AR)的作用的信息很少且相互矛盾,并且在大多数情况下并未使用性激素拮抗剂在临床实践中考虑。在这项研究中,我们分析了一组尚未在SGT中广泛研究的性激素受体(ERα,PgR,AR,还有ERβ和GPR30),以定义其表达模式以及在一系列病例中的预后和预测价值69良性和恶性SGT。我们显示AR在粘液表皮样和肿瘤细胞中的异常表达,胞浆ERβ表达与肿瘤分级之间的密切关系,以及核GPR30表达与SGT患者的无病生存率(DFS)密切相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号